stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) EPS (diluted)
Cogent Biosciences, Inc.'s EPS (diluted) for fiscal 2025 was −$2.16, compared with −$1.94 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.16. Over the past ten years it has ranged from −$16.17 (fiscal 2020) to −$1.87 (fiscal 2021); the current reading is higher than 82% of that period. Cogent Biosciences, Inc. ranks 333rd of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.16 | — |
| FY2024 | −$1.94 | — |
| FY2023 | −$2.42 | — |
| FY2022 | −$2.39 | — |
| FY2021 | −$1.87 | — |
| FY2020 | −$16.17 | — |
| FY2019 | −$4.16 | — |
| FY2018 | −$5.56 | — |
| FY2017 | −$10.00 | — |
| FY2016 | −$7.11 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.52 | — |
| Mar 2026 | −$0.53 | — |
| Dec 2025 | −$0.61 | — |
| Sep 2025 | −$0.50 | — |
| 34 more quarters | Free account |
Against its own ten years
Low −$16.17
High −$1.87
Ten-year median
−$2.59
Current reading's percentile
82
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ERAS Erasca, Inc. compare | −$0.95 |
| TVTX Travere Therapeutics, Inc. compare | −$1.29 |
| PTCT PTC Therapeutics, Inc. compare | −$1.40 |
| COGT Cogent Biosciences, Inc. | −$2.16 |
| SRRK Scholar Rock Holding Corporation compare | −$3.32 |
| DNTH Dianthus Therapeutics, Inc. compare | −$3.99 |
| KOD Kodiak Sciences Inc. compare | −$4.19 |
| CRSP CRISPR Therapeutics AG compare | −$4.74 |
| MANE Veradermics Incorporated compare | −$45.88 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on COGT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement